Tempest reports third quarter 2026 financial results
Net loss was $3.6 million with $0.9 million cash and going-concern doubt; it licensed Senlang's CD7-targeted in vivo CAR-T platform and secured a $50 million equity line.
See the latest news and media coverage for Tempest. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage CAR T biotechnology company
tempesttx.comLast updated
In short: Tempest licensed Senlang’s CAR-T platform as third-quarter results showed $0.9 million cash and going-concern doubt
Net loss was $3.6 million with $0.9 million cash and going-concern doubt; it licensed Senlang's CD7-targeted in vivo CAR-T platform and secured a $50 million equity line.
The company advanced the TPST-4003 pipeline with a Senlang collaboration and raised $2 million via warrant inducement.
The company announced positive TPST-2003 trial data, appointed Andrew Fang as Head of Business Development, and reported a net loss of $27.7 million with cash at $1.8 million.
The company reported a net loss of $26.3 million, acquired CAR-T assets from Factor Bioscience, appointed a new CEO, and announced positive interim data for TPST-2003.
Nine California biotechs are cutting at least half their staffs, including two closures, as more than 1,000 biopharma jobs are affected statewide this year.
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T...
Tempest’s lead product candidate, ... to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective...
Tempest Therapeutics (Nasdaq: TPST) has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. to potentially license Senlang's CD7-targeted lentiviral vector platform...
Track Tempest and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Tempest and other trending companies.